Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia

NCT03811223 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Familial Dysbetalipoproteinemia
Hyperlipoproteinemia Type III

Interventions

DRUG: Evolocumab Auto-Injector [Repatha]
DRUG: Placebos

Sponsor

UMC Utrecht

Collaborators

[object Object]
[object Object]
[object Object]